Eli Lilly and Company $LLY Shares Purchased by PGGM Investments

Key Points

• PGGM Investments significantly increased its holding in Eli Lilly, raising its position by 478.3% in the second quarter, totaling 96,769 shares valued at approximately $75.4 million.
• Eli Lilly's stock showed a strong performance with an earnings per share of $6.31 reported, exceeding analyst expectations of $5.59, alongside a year-on-year revenue increase of 37.6%.
• Analyst ratings for Eli Lilly have varied recently, with some firms lowering their target prices, while the average consensus remains a Moderate Buy with a price target of about $939.61.

PGGM Investments increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 478.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 96,769 shares of the company's stock after acquiring an additional 80,035 shares during the quarter. PGGM Investments' holdings in Eli Lilly and Company were worth $75,434,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. Brighton Jones LLC boosted its position in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after acquiring an additional 40 shares during the last quarter. Gradient Investments LLC boosted its position in shares of Eli Lilly and Company by 80.1% during the 1st quarter. Gradient Investments LLC now owns 670 shares of the company's stock valued at $553,000 after acquiring an additional 298 shares during the last quarter. Merit Financial Group LLC boosted its position in shares of Eli Lilly and Company by 23.1% during the 1st quarter. Merit Financial Group LLC now owns 25,303 shares of the company's stock valued at $20,898,000 after acquiring an additional 4,752 shares during the last quarter. Finally, ST Germain D J Co. Inc. boosted its position in shares of Eli Lilly and Company by 3.4% during the 1st quarter. ST Germain D J Co. Inc. now owns 1,667 shares of the company's stock valued at $1,377,000 after acquiring an additional 55 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 5.0%

Shares of NYSE:LLY opened at $763.01 on Wednesday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a market capitalization of $722.16 billion, a PE ratio of 49.87, a price-to-earnings-growth ratio of 1.01 and a beta of 0.47. The firm's 50-day moving average is $733.15 and its two-hundred day moving average is $765.96. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the firm earned $3.92 earnings per share. The business's quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity

In other news, EVP Daniel Skovronsky bought 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares of the company's stock, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO David A. Ricks bought 1,632 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders bought 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price on the stock. in a research report on Sunday, August 17th. Leerink Partners reaffirmed a "market perform" rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Finally, Leerink Partnrs cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.